. 2014 Jun;4(6):a018523. doi: 10.1101/cshperspect.a018523

Table 1.

Overview of tuberculosis vaccines in clinical trial

Vaccine name	Target indication	Antigen name or Rv number	Antigen function	Delivery system	Descriptive notes	Phase	Reference(s)
MTBVAC	Preventive	NA	NA	Live mycobacteria	Attenuated MTB with two gene deletions	I	Arbues et al. 2013
VPM 1002	Preventive	NA	NA	Live rBCG strain expressing listeriolysin, urease-deleted	Improved antigenicity due to perforation of phagosome membrane	IIa	Grode et al. 2005, 2013
Ad5 Ag85A	Preventive	Ag85A	Mycolyltransferase	Adenovirus 5 vector	Replication-deficient viral delivery system	I	Smaill et al. 2013
Ad35/MVA85A	Preventive	Ag85A, Ag85B	Mycolyltransferase	Adenovirus 35 and modified vaccinia Ankara vector	Prime boost combination of two viral delivery systems	I	Radosevic et al. 2007; Abel et al. 2010
Ad35/MVA85A	Preventive	TB10.4	Virulence factor	Adenovirus 35 and modified vaccinia Ankara vector	Prime boost combination of two viral delivery systems	I	Radosevic et al. 2007; Abel et al. 2010
Ad35/AERAS-402	Preventive	Ag85A, Ag85B	Mycolyltransferase	Adenovirus 35 vector + modified vaccinia Ankara virus	Replication-deficient viral delivery system	IIa	Radosevic et al. 2007; Abel et al. 2010
Ad35/AERAS-402	Preventive	TB10.4	Virulence factor	Adenovirus 35 vector + modified vaccinia Ankara virus	Replication-deficient viral delivery system	IIa	Radosevic et al. 2007; Abel et al. 2010
H4/IC31	Preventive	Ag85B	Mycolyltransferase	IC31	Formulation of cationic peptide and a synthetic TLR-9 agonist	IIa	Dietrich et al. 2005; Aagaard et al. 2009; Billeskov et al. 2012
H4/IC31	Preventive	TB10.4	Virulence factor	IC31		IIa
MVA85A	Preventive	Ag85A	Mycolyltransferase	Modified vaccinia Ankara	Replication-deficient viral delivery system	IIb	McShane et al. 2004; Beveridge et al. 2007; Verreck et al. 2009; Tameris et al. 2013; White et al. 2013
M72	Preventive; postexposure	Rv1196Rv0125	PPE family proteinPeptidase	AS01E	Liposomes incorporating the TLR-4 agonist MPL	IIa	Reed et al. 2009; Day et al. 2013; Leroux-Roels et al. 2013
ID93	Preventive/Postexposure/Therapeutic	Rv2608	PPE family protein	GLA-SE	Synthetic TLR-4 agonist in oil-in-water emulsion	I	Bertholet et al. 2010; Coler et al. 2013
		Rv3619, Rv3620	Virulence factor
		Rv1813	Latency-associated protein
H1/H56/IC31	Preventive/Postexposure/Therapeutic	Ag85B	Mycolyltransferase	IC31	Formulation of cationic peptide and a synthetic TLR-9 agonist	IIa	Weinrich Olsen et al. 2001; van Dissel et al. 2010; Aagaard et al. 2011
		ESAT-6	Virulence factor
		Rv2660c	Latency-associated protein
RUTI	Therapeutic	N/A	N/A	Whole fragmented Mtb		I	Cardona 2006
Mycobacterium vaccae	Therapeutic	N/A	N/A	Whole killed mycobacteria		III	deBruyn and Garner 2010; von Reyn et al. 2010; Yang et al. 2011
Mycobacterium indicus pranii	Therapeutic	N/A	N/A	Whole killed mycobacteria		III	Gupta et al. 2012a

NA, not applicable.